Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / LTRN - Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript


LTRN - Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

2024-03-18 23:14:02 ET

Lantern Pharma Inc. (LTRN)

Q4 2023 Earnings Conference Call

March 18, 2024, 04:30 PM ET

Company Participants

Panna Sharma - President and Chief Executive Officer

David Margrave - Chief Financial Officer

Conference Call Participants

John Vandermosten - Zacks Small Cap

Presentation

Operator

Good afternoon, and welcome to our Fourth Quarter and Year End 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation.

A webcast replay of today’s conference call will be available on our website at lanternpharma.com shortly after the call. We issued a press release after market close today summarizing our financial results and progress across the company for the fourth quarter ended December 31, 2023. A copy of this release is available through our website @lanternpharma.com where you will also find a link to the slides management will be referencing on today’s call.

We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including results of clinical trials and the impact of competition.

Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2023, which is on file with the SEC and available on our website. Forward-looking statements made on this conference call are as of today, March 18, 2024, and Lantern Pharma does not intend to update any of these forward-looking statements to reflect events from circumstances that occur after today, unless required by law.

The webcast replay of the conference call and webinar will be available on Lantern’s website. On today’s webcast, we have Lantern Pharma’s CEO, Panna Sharma; and CFO, David Margrave, Panna will start things off with an overview of Lantern’s strategy and business model and highlight recent achievements in our operations, after which David will discuss our financial results. This will be followed by some concluding comments from Panna, and then we’ll open the call for Q&A....

For further details see:

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Stock Information

Company Name: Lantern Pharma Inc.
Stock Symbol: LTRN
Market: NASDAQ
Website: lanternpharma.com

Menu

LTRN LTRN Quote LTRN Short LTRN News LTRN Articles LTRN Message Board
Get LTRN Alerts

News, Short Squeeze, Breakout and More Instantly...